Table 3.
Two‐step multivariate analysis of the prognostic factors for patients with gastric cancer after neoadjuvant therapy
| Variables | Relative risk (95% CI) | p value |
|---|---|---|
| Development cohort | ||
| Step 1 | ||
| Age | 1.161 (1.075–1.253) | <.001 |
| Race | 0.987 (0.962–1.013) | .325 |
| Site | 1.001 (0.999–1.003) | .190 |
| Histological type | 1.300 (1.133–1.491) | <.001 |
| Size | 1.000 (0.998–1.001) | .696 |
| Surgical procedure | 1.169 (1.079–1.266) | <.001 |
| Grade | 0.998 (0.995–1.000) | .087 |
| LN examined | 0.751 (0.665–0.848) | <.001 |
| ypTNM staging (AJCC 8th) | 1.717 (1.561–1.888) | <.001 |
| Step 2 | ||
| Age | 1.164 (1.078–1.257) | <.001 |
| Race | 0.988 (0.960–1.016) | .388 |
| Site | 1.001 (0.999–1.002) | .355 |
| Histological type | 1.260 (1.098–1.446) | .001 |
| Size | 1.000 (0.998–1.001) | .850 |
| Surgical procedure | 1.14 (1.061–1.245) | .001 |
| Grade | 0.998 (0.995–1.000) | .106 |
| LN examined | 0.661 (0.583–0.749) | <.001 |
| ypTNM staging (AJCC 8th) | 1.018 (0.880–1.179) | .807 |
| Modified ypTNM staging | 1.540 (1.403–1.691) | <.001 |
| Validation cohort | ||
| Step 1 | ||
| Site | 0.889 (0.725–1.089) | .255 |
| Size | 1.008 (1.000–1.016) | .047 |
| Grade | 1.001 (0.994–1.008) | .748 |
| ypTNM staging (AJCC 8th) | 1.892 (1.463–2.446) | <.001 |
| Step 2 | ||
| Site | 0.924 (0.755–1.131) | .445 |
| Size | 1.007 (0.999–1.015) | .080 |
| Grade | 1.002 (0.995–1.009) | .590 |
| ypTNM staging (AJCC 8th) | 0.965 (0.630–1.476) | .868 |
| Modified ypTNM staging | 1.636 (1.278–2.096) | <.001 |
Step 1, with consideration of all significantly important prognostic factors in univariate analysis except for the modified ypTNM stage; step 2, with consideration of all significantly important prognostic factors in univariate analysis, including the modified ypTNM stage.
Abbreviations: AJCC 8th, American Joint Committee on Cancer 8th edition; CI, confidence interval; LN, lymph node.